Skip to main content

Publisher: Taylor and Francis Ltd

Volume 22, Number 2, 1 March 2012

Favourites:
ADD
Favourites:
ADD
Favourites:
ADD

A Bayesian Dose-Finding Design Adapting to Efficacy and Tolerability Response
pp. 276-293(18)
Authors: Padmanabhan, S. Krishna; Berry, Scott; Dragalin, Vladimir; Krams, Michael

Favourites:
ADD

An Adaptive Group Sequential Phase II Design to Compare Treatments for Survival Endpoints in Rare Patient Entities
pp. 294-311(18)
Authors: Wunder, Christina; Kopp-Schneider, Annette; Edler, Lutz

Favourites:
ADD

Phase II Cancer Clinical Trials with Heterogeneous Patient Populations
pp. 312-328(17)
Authors: Jung, Sin-Ho; Chang, Myron N.; Kang, Sun J.

Favourites:
ADD

Missing Data Mechanisms in a Dose-Finding Adaptive Trial
pp. 329-337(9)
Authors: Liu, Kenneth; Entsuah, Richard

Favourites:
ADD

Stopping Guidelines for Harm in a Study Designed to Establish the Safety of a Marketed Drug
pp. 338-350(13)
Authors: Fleishman, Alex N.; Parker, Robert A.

Favourites:
ADD

Sample Size Determination for Alternate Periods of Use Study Designs with Binary Responses
pp. 351-367(17)
Authors: Morel, Jorge G.; Neerchal, Nagaraj K.

Favourites:
ADD

Test Procedures for Disease Prevalence with Partially Validated Data
pp. 368-386(19)
Authors: Tang, Man-Lai; Qiu, Shi-Fang; Poon, Wai-Yin; Tang, Nian-Sheng

Favourites:
ADD

Delayed Effects in the Exposure-Response Analysis of Clinical QTc Trials
pp. 387-400(14)
Authors: Glomb, Patricia; Ring, Arne

Favourites:
ADD

Average Cost-Effectiveness Ratio with Censored Data
pp. 401-415(15)
Authors: Bang, Heejung; Zhao, Hongwei

Favourites:
ADD
Favourites:
ADD
Favourites:
ADD

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content